New & Novel
A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma
Cancers 2022 May 20 [Link] Irene Dell’Anno, Alessandra Melani, Sarah A Martin, Marcella Barbarino, Roberto Silvestri, Monica Cipollini, Antonio Giordano, Luciano Mutti, Andrea Nicolini, Luca Luzzi, Raffaele Aiello, Federica Gemignani, Stefano Landi Abstract The lack of effective therapies remains one of the main challenges for malignant pleural mesothelioma (MPM). In this perspective, drug repositioning could…
Read MoreGeneration and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Journal of Visualized Experiments 2022 April 21 [Link] Tamara M Griffiths, Carlos Ramos, Cara L Haymaker Abstract Current methodologies for the expansion of primary tumor cell lines from rare tumor types are lacking. This protocol describes methods to expand primary tumor cells from surgically resected, malignant pleural mesothelioma (MPM) by providing a complete overview of…
Read MoreFeasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data
Cancers 2022 April 16 [Link] Tugce Kutuk, Haley Appel, Maria Carolina Avendano, Federico Albrecht, Paul Kaywin, Suyen Ramos, Melanie E Suarez-Murias, Minesh P Mehta, Rupesh Kotecha Abstract Purpose: The objectives of this study were to evaluate the implementation, device usage rates, clinical outcomes, and treatment-related toxicities associated with TTFields and pemetrexed plus platinum-based chemotherapy in…
Read MoreRetinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy
Frontiers in Oncology 2022 March 24 [Link] Caitlin M Tilsed , Thomas H Casey, Emma de Jong, Anthony Bosco, Rachael M Zemek, Joanne Salmons, Graeme Wan, Michael J Millward, Anna K Nowak, Richard A Lake, Willem Joost Lesterhuis Abstract With immune checkpoint therapy (ICT) having reshaped the treatment of many cancers, the next frontier is…
Read MoreExhaled breath to screen for malignant pleural mesothelioma: a validation study
The European Respiratory Journal 2017 December 21 [Link] Lamote K, Vynck M, Thas O, Van Cleemput J, Nackaerts K, van Meerbeeck JP Abstract Malignant pleural mesothelioma (MPM) is predominantly caused by asbestos exposure and has a poor prognosis. Breath contains volatile organic compounds (VOCs) and can be explored as an early detection tool. Previously, we…
Read MoreEstimating past inhalation exposure to asbestos: A tool for risk attribution and disease screening
International Journal of Hygiene and Environmental Health 2017 October 7 [Epub ahead of print] [Link] Cherrie JW, McElvenny D, Blyth KG Abstract INTRODUCTION: Late presentation is common in mesothelioma. Reliable assessment of past exposure to asbestos is a necessary first step for risk attribution and for the development of a future screening programme. Such a…
Read MoreChimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
Cancers 2017 September [Link] Klampatsa A, Haas AR, Moon EK, Albelda SM Abstract Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes in leukemias and is now being explored in solid tumors. CARs…
Read MoreMalignant Pleural Mesothelioma: State of the art and advanced cell therapy
European Journal of Medicinal Chemistry 2017 August [Epub ahead of print] [Link] Facchetti G, Petrella F, Spaggiari L, Rimoldi I Abstract Malignant Pleural Mesothelioma (MPM) is an aggressive malignancy highly resistant to chemotherapy, with a response rate of 20% of patients and for this reason an efficient treatment is still a challenge. Platinum-based chemotherapy in…
Read MoreIntraoperative adjuncts for malignant pleural mesothelioma
Translational Lung Cancer Research 2017 June [Link] Chan WH, Sugarbaker DJ, Burt BM Abstract Malignant pleural mesothelioma (MPM) is a rapidly fatal disease. Multimodality surgically based therapies may extend survival in select patients, however, local relapse after resection is common. Novel intraoperative adjunctive therapies including heated intraoperative chemotherapy (HIOC), heated intraoperative povidone-iodine (PVP-I), and photodynamic…
Read MoreNovel systemic therapy against malignant pleural mesothelioma
Translational Lung Cancer Research 2017 June [Link] Mancuso MR, Neal JW Abstract Malignant pleural mesothelioma is an aggressive tumor of the pleura with an overall poor prognosis. Even with surgical resection, for which only a subset of patients are eligible, long term disease free survival is rare. Standard first-line systemic treatment consists of a platinum…
Read More